Am J Cancer Res 2013;3(4):347-355

Review Article
BLT2 is a pro-tumorigenic mediator during cancer progression and a
therapeutic target for anti-cancer drug development

Nam-Kyu Cho, Young-Chul Joo, Jun Dong Wei, Jae In Park, Jae-Hong Kim

College of Life Sciences and Biotechnology, Korea University, Seoul 136-701, Korea

Received June 15, 2013; Accepted July 21, 2013; Epub August 14, 2013; Published August 30, 2013

Abstract: Cancer is a leading cause of death worldwide and has been linked to inflammation. Leukotriene B4 (LTB4) is
synthesized from arachidonic acid via the 5-lipoxygenase pathway and is a potent chemoattractant for inflammatory cells. LTB4
was recently shown to be associated with the pathogenesis of inflammatory diseases, including cancer. Of the two known LTB4
receptors, BLT1 and BLT2, the biological roles of the low-affinity LTB4 receptor 2, BLT2, have only recently been elucidated. This
review focuses on recent discoveries regarding BLT2 and its roles in cancer progression and the downstream signaling
mechanisms of the BLT2-linked signaling cascade in cancer cells. We believe that these findings will facilitate the development
of new cancer treatments. (ajcr0000210).

Keywords: Leukotriene B4 receptor 2 (BLT2), leukotriene B4, NADPH oxidase, reactive oxygen species, nuclear factor-kB, cancer
progression

Address correspondence to: Dr. Jae-Hong Kim, College of Life Sciences and Biotechnology, Korea University, 5-1 Anam-dong,
Sungbuk-gu, Seoul, 136-701, Korea. Tel: 82-2-3290-3452; Fax: 82-2-927-9028; E-mail: jhongkim@korea.ac.kr
AJCR Copyright © 2010-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711, USA
American Journal of Cancer Research
ISSN: 2156-6976